Edwards Lifesciences Q4 2025 Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy EW?
Source: seekingalpha
- Earnings Highlights: Edwards Lifesciences reported a Q4 2025 non-GAAP EPS of $0.58, missing estimates by $0.04, while revenue reached $1.57 billion, a 13.8% year-over-year increase, exceeding expectations by $30 million, indicating strong market performance.
- Cash Position: As of December 31, 2025, the company held approximately $3.0 billion in cash and cash equivalents against total debt of about $600 million, demonstrating solid financial health that supports future investments and expansion.
- Growth Outlook: Edwards has increased confidence in achieving its 2026 sales growth rate guidance of 8% to 10%, with EPS expectations ranging from $2.90 to $3.05, reflecting an optimistic view of future performance.
- Q1 Projections: The company projects total sales for Q1 2026 to be between $1.55 billion and $1.63 billion, with adjusted EPS of $0.70 to $0.76, showcasing ongoing growth potential and market demand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EW
Wall Street analysts forecast EW stock price to rise
24 Analyst Rating
16 Buy
8 Hold
0 Sell
Moderate Buy
Current: 76.440
Low
84.00
Averages
96.52
High
105.00
Current: 76.440
Low
84.00
Averages
96.52
High
105.00
About EW
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Edwards Lifesciences to Participate in Citi Medtech Access Day
- Event Participation: Edwards Lifesciences Corporation announced its participation in Citi's Unplugged Medtech and Life Sciences Access Day on February 26, 2026, where CFO Scott Ullem will present at 10:15 a.m. ET, showcasing the company's latest advancements in structural heart innovation.
- Live Webcast: The presentation will be available via live webcast on Edwards Lifesciences' investor relations website, allowing investors and the public to watch in real-time, with an archived version accessible later the same day to ensure broad dissemination and transparency of information.
- Company Background: Edwards Lifesciences is a leading global structural heart innovation company focused on improving patient lives through breakthrough technologies and partnerships with clinicians and healthcare stakeholders, demonstrating its leadership position in the medical industry.
- Brand Communication: The company actively promotes its brand and innovations through social media platforms such as LinkedIn, Facebook, Instagram, and YouTube, aiming to enhance public awareness of its products and services, thereby further solidifying its market position.
See More
Analyzing Earnings in the Healthcare Sector: AZN, EW, and ZBH Compared
Earnings Reports in Healthcare Sector: Companies in the healthcare sector are reporting earnings that provide insights into their development progress and potential growth opportunities, particularly with the release of new drugs and medical devices.
AstraZeneca's Strong Performance: AstraZeneca reported a strong quarterly performance, with significant sales growth driven by its cancer medicines, which accounted for a large portion of its revenue, prompting positive investor sentiment.
Zimmer Biomet's Market Position: Zimmer Biomet is experiencing high demand for its orthopedic products, contributing to revenue growth, although it faces challenges from tariffs that may impact future earnings.
Investment Recommendations: Analysts are recommending specific stocks in the healthcare sector for investors to consider, highlighting potential growth opportunities and the importance of monitoring earnings and market conditions.
See More
Halper Sadeh LLC Investigates Edwards Lifesciences for Potential Fiduciary Breaches
- Investigation Context: Halper Sadeh LLC is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders, which could impact corporate governance and shareholder rights.
- Shareholder Rights Protection: Long-term shareholders of Edwards may have the opportunity to seek corporate governance reforms, return of funds, or court-approved financial incentives, directly affecting investment returns and company transparency.
- Legal Fee Arrangement: The firm will handle the case on a contingent fee basis, meaning shareholders will not be responsible for out-of-pocket legal fees or expenses, reducing the financial risk of participation and encouraging more shareholders to get involved.
- Importance of Participation: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, thereby enhancing transparency and management effectiveness, ultimately contributing to increased shareholder value.
See More
Edwards Lifesciences Q4 Earnings Analysis
- Earnings Performance: Edwards Lifesciences reported Q4 earnings of 58 cents per share, missing the 62 cents consensus, yet revenue of $1.57 billion exceeded the $1.54 billion target, indicating resilience in revenue growth despite the earnings miss.
- Stock Price Reaction: Following the earnings report, EW's stock rose over 2%, suggesting investor confidence in the company's future prospects, which may reflect a market focus on revenue growth rather than earnings shortfalls.
- Options Market Dynamics: In the options market, put implied volatility is higher than call implied volatility, indicating investor concern over downside risks, while call implied volatility rises at upper boundaries, reflecting demand for upside potential, suggesting expectations of future volatility.
- Future Price Expectations: The Black-Scholes model anticipates that Edwards Lifesciences stock will trade between $74 and $82.91 by the March 20 expiration, providing a framework for traders to strategize based on market expectations for future price movements.
See More
Edwards Lifesciences Q4 2025 Earnings Call Insights
- Strong Sales Growth: Edwards Lifesciences reported Q4 2025 sales of $1.57 billion, reflecting an 11.6% year-over-year increase, demonstrating robust market demand and execution in structural heart therapies, which is expected to drive sustained future performance.
- Increased Earnings Guidance: Management raised the 2026 earnings per share (EPS) guidance to $2.90 to $3.05, indicating confidence in the company's future profitability, particularly driven by the TAVR and TMTT product lines.
- Accelerated Product Innovation: The launch of new products like SAPIEN M3 and next-gen PASCAL is projected to generate TMTT sales of $740 to $780 million in 2026, further solidifying the company's leadership position in the heart valve treatment market.
- Market Strategy Adjustments: The company increased market access spending by $112 million in Q4 to address competition and market demand, showcasing its agility in responding to the rapidly changing medical device landscape.
See More
Edwards Lifesciences (EW) Earnings Transcript
See More
Edwards Lifesciences to Participate in Citi Medtech Access Day
- Event Participation: Edwards Lifesciences Corporation announced its participation in Citi's Unplugged Medtech and Life Sciences Access Day on February 26, 2026, where CFO Scott Ullem will present at 10:15 a.m. ET, showcasing the company's latest advancements in structural heart innovation.
- Live Webcast: The presentation will be available via live webcast on Edwards Lifesciences' investor relations website, allowing investors and the public to watch in real-time, with an archived version accessible later the same day to ensure broad dissemination and transparency of information.
- Company Background: Edwards Lifesciences is a leading global structural heart innovation company focused on improving patient lives through breakthrough technologies and partnerships with clinicians and healthcare stakeholders, demonstrating its leadership position in the medical industry.
- Brand Communication: The company actively promotes its brand and innovations through social media platforms such as LinkedIn, Facebook, Instagram, and YouTube, aiming to enhance public awareness of its products and services, thereby further solidifying its market position.
See More
Analyzing Earnings in the Healthcare Sector: AZN, EW, and ZBH Compared
Earnings Reports in Healthcare Sector: Companies in the healthcare sector are reporting earnings that provide insights into their development progress and potential growth opportunities, particularly with the release of new drugs and medical devices.
AstraZeneca's Strong Performance: AstraZeneca reported a strong quarterly performance, with significant sales growth driven by its cancer medicines, which accounted for a large portion of its revenue, prompting positive investor sentiment.
Zimmer Biomet's Market Position: Zimmer Biomet is experiencing high demand for its orthopedic products, contributing to revenue growth, although it faces challenges from tariffs that may impact future earnings.
Investment Recommendations: Analysts are recommending specific stocks in the healthcare sector for investors to consider, highlighting potential growth opportunities and the importance of monitoring earnings and market conditions.
See More
Halper Sadeh LLC Investigates Edwards Lifesciences for Potential Fiduciary Breaches
- Investigation Context: Halper Sadeh LLC is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders, which could impact corporate governance and shareholder rights.
- Shareholder Rights Protection: Long-term shareholders of Edwards may have the opportunity to seek corporate governance reforms, return of funds, or court-approved financial incentives, directly affecting investment returns and company transparency.
- Legal Fee Arrangement: The firm will handle the case on a contingent fee basis, meaning shareholders will not be responsible for out-of-pocket legal fees or expenses, reducing the financial risk of participation and encouraging more shareholders to get involved.
- Importance of Participation: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, thereby enhancing transparency and management effectiveness, ultimately contributing to increased shareholder value.
See More
Edwards Lifesciences Q4 Earnings Analysis
- Earnings Performance: Edwards Lifesciences reported Q4 earnings of 58 cents per share, missing the 62 cents consensus, yet revenue of $1.57 billion exceeded the $1.54 billion target, indicating resilience in revenue growth despite the earnings miss.
- Stock Price Reaction: Following the earnings report, EW's stock rose over 2%, suggesting investor confidence in the company's future prospects, which may reflect a market focus on revenue growth rather than earnings shortfalls.
- Options Market Dynamics: In the options market, put implied volatility is higher than call implied volatility, indicating investor concern over downside risks, while call implied volatility rises at upper boundaries, reflecting demand for upside potential, suggesting expectations of future volatility.
- Future Price Expectations: The Black-Scholes model anticipates that Edwards Lifesciences stock will trade between $74 and $82.91 by the March 20 expiration, providing a framework for traders to strategize based on market expectations for future price movements.
See More
Edwards Lifesciences Q4 2025 Earnings Call Insights
- Strong Sales Growth: Edwards Lifesciences reported Q4 2025 sales of $1.57 billion, reflecting an 11.6% year-over-year increase, demonstrating robust market demand and execution in structural heart therapies, which is expected to drive sustained future performance.
- Increased Earnings Guidance: Management raised the 2026 earnings per share (EPS) guidance to $2.90 to $3.05, indicating confidence in the company's future profitability, particularly driven by the TAVR and TMTT product lines.
- Accelerated Product Innovation: The launch of new products like SAPIEN M3 and next-gen PASCAL is projected to generate TMTT sales of $740 to $780 million in 2026, further solidifying the company's leadership position in the heart valve treatment market.
- Market Strategy Adjustments: The company increased market access spending by $112 million in Q4 to address competition and market demand, showcasing its agility in responding to the rapidly changing medical device landscape.
See More
Edwards Lifesciences (EW) Earnings Transcript
See More
